Ludwig Cancer Research and Cancer Research Institute launch cancer clinical trial
(Ludwig Institute for Cancer Research) Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI ® (durvalumab) for advanced ovarian and colorectal cancers.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | International Medicine & Public Health | Ovarian Cancer | Ovaries | Virotherapy